department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

azenosertib · pharmadog

pharmadog
drugs
azenosertib

drug

patient view →

azenosertib

Phase 2updated 2mo ago

by $ZNTL Zentalis Pharmaceuticals, Inc.

Phase 2

community read0 votes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

generic

azenosertib [INN]

indication

Endometrial Cancer

phase

phase_2

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Trials studying azenosertib

phase3A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expressionrecruitingn=420
phase2A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancerrecruitingn=310
phase1A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancerrecruitingn=172
phase1A Study of Azenosertib (ZN-c3) in Combination With Gemcitabine in Subjects With Osteosarcomacompletedn=31
phase2A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinomacompletedn=92
phase2A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancercompletedn=117
phase1A Study of Azenosertib (ZN-c3) in Participants With Solid Tumorscompletedn=274
EP1Targeted Pathway Inhibition in Patients With Pancreatic Cancerrecruitingn=90

more trials →